GLOBUS MEDICAL, INC. Net Change in Cash
GLOBUS MEDICAL, INC. (GMED) reported Net Change in Cash of -$18.41 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-06
- GLOBUS MEDICAL, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was $34.79M.
- GLOBUS MEDICAL, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was -$323.17M.
- GLOBUS MEDICAL, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was -$113.23M, a 268.45% decline year-over-year.
- GLOBUS MEDICAL, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was $67.22M, a 83.06% increase year-over-year.
- GLOBUS MEDICAL, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was -$258.28M, a 181.44% decline from fiscal 2024.
- GLOBUS MEDICAL, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was $317.15M, a 0.10% increase from fiscal 2023.
- GLOBUS MEDICAL, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was $316.83M.
- GLOBUS MEDICAL, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was -$42.60M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$18.41M 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $34.79M 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | -$258.28M 10-K · filed 2026-02-24 | |||
| 2025-09-30 | -$412.67M 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | -$554.99M 10-Q · filed 2026-08-06 | |||
| 2025-03-31 | -$323.17M 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | $317.15M 10-K · filed 2026-02-24 | |||
| 2024-09-30 | $155.47M 10-Q · filed 2025-11-06 | |||
| 2024-06-30 | -$56.87M 10-Q · filed 2025-08-07 | |||
| 2024-03-31 | -$113.23M 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $316.83M 10-K · filed 2026-02-24 | |||
| 2023-09-30 | $129.15M 10-Q · filed 2024-11-05 | |||
| 2023-06-30 | $155.99M 10-Q · filed 2024-08-06 | |||
| 2023-03-31 | $67.22M 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | -$42.60M 10-K · filed 2025-02-20 | |||
| 2022-09-30 | -$58.85M 10-Q · filed 2023-11-07 | |||
| 2022-06-30 | -$42.30M 10-Q · filed 2023-08-03 | |||
| 2022-03-31 | $36.72M 10-Q · filed 2023-05-04 | |||
| 2021-12-31 | -$46.33M 10-K · filed 2024-02-21 | |||
| 2021-09-30 | $122.48M 10-Q · filed 2022-11-08 | |||
| 2021-06-30 | $29.39M 10-Q · filed 2022-08-04 | |||
| 2021-03-31 | -$54.55M 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | $43.67M 10-K · filed 2023-02-21 | |||
| 2020-09-30 | $54.88M 10-Q · filed 2021-11-04 | |||
| 2020-06-30 | -$30.17M 10-Q · filed 2021-08-04 | |||
| 2020-03-31 | -$28.98M 10-Q · filed 2021-05-04 | |||
| 2019-12-31 | $55.98M 10-K · filed 2022-02-17 | |||
| 2019-09-30 | $26.44M 10-Q · filed 2020-10-28 | |||
| 2019-06-30 | -$21.96M 10-Q · filed 2020-08-05 | |||
| 2018-12-31 | $20.93M 10-K · filed 2021-02-17 | |||
| 2017-12-31 | $51.39M 10-K · filed 2019-02-21 | |||
| 2016-12-31 | -$16.34M 10-K · filed 2019-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSULET CORP (PODD) | United States | $9.420B | 28.12 |
| GLAUKOS Corp (GKOS) | United States | $9.135B | -43.73 |
| BAXTER INTERNATIONAL INC (BAX) | United States | $12.139B | -10.35 |
| Penumbra Inc (PEN) | United States | $12.596B | 77.33 |
| MiniMed Group, Inc. (MMED) | United States | $5.748B | -16.85 |
| MERIT MEDICAL SYSTEMS INC (MMSI) | United States | $5.212B | 28.44 |
| TELEFLEX INC (TFX) | United States | $5.093B | -5.44 |
| Solventum Corp (SOLV) | United States | $15.085B | 9.16 |
| HAEMONETICS CORP (HAE) | United States | $4.821B | 36.52 |
| Heartflow, Inc. (HTFL) | United States | $4.225B |